Literature DB >> 9867143

Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters.

P D Mozley1, J B Stubbs, K Plössl, S H Dresel, E D Barraclough, A Alavi, L I Araujo, H F Kung.   

Abstract

UNLABELLED: Technetium-99m TRODAT-1 is an analog of cocaine that selectively binds the presynaptic dopamine transporters. The primary purpose of this study was to measure its whole-body biokinetics and radiation dosimetry in healthy human volunteers. The study was conducted within a regulatory framework that required its pharmacological safety to be assessed simultaneously.
METHODS: The sample included 4 men and 6 women ranging in age from 22-54 yr. An average of 20 whole-body scans were acquired sequentially on a dual-head camera for up to 46 hr after the intravenous administration of 370+/-16 MBq (10.0+/-0.42 mCi) 99mTc TRODAT. The renal excretion fractions were measured from 12-24 discrete urine specimens. The fraction of the administered dose in 17 regions of interest and each urine specimen was quantified from the attenuation and background corrected geometric mean counts in conjugate views. Multiexponential functions were iteratively fit to each time-activity curve using a nonlinear, least squares regression algorithm. These curves were numerically integrated to yield source organ residence times. Gender-specific radiation doses were then estimated with the Medical Internal Radiation Dose technique for each subject individually before any results were averaged.
RESULTS: There were no pharmacological effects of the radiotracer on any of the subjects. The early planar images showed differentially increased activity in the nose, pudendum and stomach. SPECT images demonstrated that the radiopharmaceutical localized in the basal ganglia in a distribution that was consistent with selective transporter binding. Image analysis showed that the kidneys excreted between 20% and 32% of the injected dose during the first 22-28 hr postadministration, after which no more activity could be recovered in the urine. The dose limiting organ in both men and women was the liver, which received an average of 0.046 mGy/MBq (0.17 rads/mCi, range 0.14-0.22 rad/mCi). In the worst case, which was clearly an over-estimation, it would have taken 22.7 mCi to deliver 5 rad to the liver.
CONCLUSION: TRODAT may be a safe and effective radiotracer for imaging dopamine transporters in the brain and the body.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9867143

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Biodistribution and Internal Radiation Dosimetry of 99mTc-IDA-D-[c(RGDfK)]2 (BIK-505), a Novel SPECT Radiotracer for the Imaging of Integrin αvβ3 Expression.

Authors:  Yoo Sung Song; Joong Hyun Kim; Byung Chul Lee; Jae Ho Jung; Hyun Soo Park; Sang Eun Kim
Journal:  Cancer Biother Radiopharm       Date:  2018-08-22       Impact factor: 3.099

2.  Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease.

Authors:  Randel L Swanson; Andrew B Newberg; Paul D Acton; Andrew Siderowf; Nancy Wintering; Abass Alavi; P David Mozley; Karl Plossl; Michelle Udeshi; Howard Hurtig
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

3.  Higher striatal dopamine transporter density in PTSD: an in vivo SPECT study with [(99m)Tc]TRODAT-1.

Authors:  Marcelo Q Hoexter; Gustavo Fadel; André C Felício; Mariana B Calzavara; Ilza R Batista; Marilia A Reis; Ming C Shih; Roger K Pitman; Sérgio B Andreoli; Marcelo F Mello; Jair J Mari; Rodrigo A Bressan
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

4.  Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients.

Authors:  G J E Schmitt; T Frodl; S Dresel; C la Fougère; R Bottlender; N Koutsouleris; K Hahn; H-J Möller; E M Meisenzahl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-15       Impact factor: 5.270

5.  Calix[n]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine.

Authors:  Leonardo da Silva Neto; Angélica Faleiros da Silva Maia; Adriana Martins Godin; Paulo Sérgio de Almeida Augusto; Raissa Lima Gonçalves Pereira; Sordaini Maria Caligiorne; Rosemeire Brondi Alves; Simone Odília Antunes Fernandes; Valbert Nascimento Cardoso; Gisele Assis Castro Goulart; Felipe Terra Martins; Maila de Castro Lourenço das Neves; Frederico Duarte Garcia; Ângelo de Fátima
Journal:  J Adv Res       Date:  2021-09-13       Impact factor: 12.822

6.  Optimization of imaging parameters for SPECT scans of [99mTc]TRODAT-1 using Taguchi analysis.

Authors:  Cheng-Kai Huang; Jay Wu; Kai-Yuan Cheng; Lung-Kwang Pan
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

7.  The feasibility of using CT-guided ROI for semiquantifying striatal dopamine transporter availability in a hybrid SPECT/CT system.

Authors:  Chien-Chin Hsu; Yen-Hsiang Chang; Wei-Che Lin; Shu-Wen Tang; Pei-Wen Wang; Yung-Cheng Huang; Nan-Tsing Chiu
Journal:  ScientificWorldJournal       Date:  2014-11-02

8.  Correlative (99m)tc-labeled tropane derivative single photon emission computer tomography and clinical assessment in the staging of Parkinson disease.

Authors:  Ajit S Shinto; Joppy Antony; Koramadai Kamaleshwaran; Krishnan Vijayan; Arul Selvan; Aruna Korde; Mythili Kameshwaran; Grace Samuel
Journal:  World J Nucl Med       Date:  2014-09

9.  In-house Preparation and Quality Control of Tc99m TRODAT 1 for Diagnostic Single-photon Emission Computed Tomography/Computed Tomography Imaging in Parkinson's Disease.

Authors:  Rakhee Vatsa; Jaya Shukla; Bhagwant Rai Mittal; Apurva Sood; Raman Kumar Joshi; Kanchan Palarwal; Priya Bhusari; Manish Modi
Journal:  Indian J Nucl Med       Date:  2017 Oct-Dec

10.  EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0.

Authors:  Silvia Morbelli; Giuseppe Esposito; Javier Arbizu; Henryk Barthel; Ronald Boellaard; Nico I Bohnen; David J Brooks; Jacques Darcourt; John C Dickson; David Douglas; Alexander Drzezga; Jacob Dubroff; Ozgul Ekmekcioglu; Valentina Garibotto; Peter Herscovitch; Phillip Kuo; Adriaan Lammertsma; Sabina Pappata; Iván Peñuelas; John Seibyl; Franck Semah; Livia Tossici-Bolt; Elsmarieke Van de Giessen; Koen Van Laere; Andrea Varrone; Michele Wanner; George Zubal; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-09       Impact factor: 9.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.